pharma news

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

PepGen slumps as FDA places hold on lead drug

Shares in PepGen fell sharply after the FDA placed a partial clinical hold on its lead drug for rare neuromuscular disease DM1.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

Hansa closes on FDA verdict for transplant drug imlifidase

The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

News

Welsh firm Antiverse raises funds for AI antibody platform

Cardiff's Antiverse has raised $9.3m to develop its AI-based design platform for antibodies against hard-to-reach targets like GPCRs and ion channels.

Alnylam bets on Tenaya RNAi tech, and other licensing news

Lilly unveils employer scheme for weight-loss drug Zepbound

PepGen slumps as FDA places hold on lead drug

Can GLP-1 drugs help tackle addiction?

Hansa closes on FDA verdict for transplant drug imlifidase

Welsh firm Antiverse raises funds for AI antibody platform

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks